Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | QPCT | Q16769 | 1/20 | 0.33 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4989159 | 0.75 | CCR1 (0.52) | MAPTKDM4ELMNACYP3A4NOS1 | |
| SCHEMBL30117375 | 0.75 | CCR1 (0.52) | MAPTKDM4ELMNACYP3A4NOS1 | |
| SCHEMBL2254387 | 0.74 | PIM1 (0.38) | PARP1PRKCIALDH1A1MAPTKDM4E | |
| SCHEMBL563678 | 0.72 | EGFR (0.37) | PRKCIQPCTQPCTL | |
| SCHEMBL29429298 | 0.72 | EGFR (0.37) | PRKCIQPCTQPCTL | |
| SCHEMBL15834705 | 0.72 | LMNA (0.44) | PARP1PRKCIALDH1A1MAPTKDM4E | |
| SCHEMBL35938 | 0.70 | LMNA (0.54) | ALDH1A1MAPTKDM4ELMNAPOLB | |
| SCHEMBL29382312 | 0.70 | LMNA (0.54) | ALDH1A1MAPTKDM4ELMNAPOLB | |
| SCHEMBL28400795 | 0.69 | LMNA (0.52) | ALDH1A1MAPTKDM4ELMNAPOLB | |
| Ammonia Solution, Strong SCHEMBL29846072 | 0.69 | LMNA (0.52) | ALDH1A1MAPTKDM4ELMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998972-B2 | 1H-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2011-08-16 | — | — | US | disclosed |
| EP-1509521-B1 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| US-20050245562-A1 | 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2005-11-03 | — | — | US | disclosed |
| EP-1509521-A2 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003097641-A2 | 1H-IMIDAZO[4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245562-A1 | 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases | ABL1, PRKCA, PRKCQ | PARP1 1373/4885PRKCI 7/4885ALDH1A1 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.